KSL10h
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
WASHINGTON — The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for ...
Health risks from wildfire smoke linger 3 years after Marshall Fire
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Hosted on MSN15h
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
McKnight's Long-Term Care News21h
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).